FGFR1 and colorectal cancer: Meanwhile, a Phase I study for FGFR1–3 inhibitor rogaratinib investigated 866 solid cancer patients, including 46 colorectal cancer patients, and showed that the tumor of only one patient had FGFR mRNA overexpression.